Novavax up on accelerated approval pathway in U.S. for NanoFlu

Novavax (NASDAQ:NVAX) is up 10% premarket on increased volume on the heels of its announcement that the FDA is on board with accelerated review status for flu vaccine NanoFlu.

The company plans to launch a Phase 3 study this fall with topline results expected in Q1 2020. If all goes well, a marketing application will follow.

https://seekingalpha.com/news/3474269-novavax-10-percent-premarket-accelerated-approval-pathway-u-s-nanoflu